Universal Beteiligungs und Servicegesellschaft mbH Sells 58,281 Shares of Kenvue Inc. (NYSE:KVUE)

Universal Beteiligungs und Servicegesellschaft mbH lowered its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 4.6% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,205,509 shares of the company's stock after selling 58,281 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.06% of Kenvue worth $28,908,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Pittenger & Anderson Inc. bought a new stake in shares of Kenvue in the first quarter valued at $30,000. TruNorth Capital Management LLC purchased a new stake in Kenvue during the first quarter valued at about $36,000. Continuum Advisory LLC lifted its holdings in Kenvue by 2,071.1% during the first quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock valued at $47,000 after purchasing an additional 1,864 shares during the last quarter. Clarity Asset Management Inc. bought a new position in Kenvue during the fourth quarter worth about $45,000. Finally, Rossby Financial LCC bought a new stake in shares of Kenvue in the first quarter valued at approximately $52,000. Institutional investors own 97.64% of the company's stock.

Kenvue Trading Up 1.5%

Shares of NYSE:KVUE traded up $0.34 during trading on Friday, reaching $22.84. 9,354,880 shares of the company traded hands, compared to its average volume of 17,220,215. The firm has a market capitalization of $43.82 billion, a price-to-earnings ratio of 41.53, a P/E/G ratio of 3.76 and a beta of 0.83. Kenvue Inc. has a 52-week low of $18.10 and a 52-week high of $25.17. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. The business's fifty day moving average is $22.05 and its 200-day moving average is $22.33.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The company had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. During the same quarter last year, the firm posted $0.28 earnings per share. The firm's revenue was down 3.9% on a year-over-year basis. As a group, analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on KVUE shares. UBS Group reduced their price objective on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating for the company in a research note on Thursday, July 17th. JPMorgan Chase & Co. reduced their price objective on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday. Citigroup decreased their price target on Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research report on Tuesday, July 15th. Redburn Atlantic assumed coverage on Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target on the stock. Finally, Barclays decreased their price target on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Tuesday, July 15th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $24.79.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.